195 related articles for article (PubMed ID: 24492735)
1. Incidence and severity of acute adverse reactions to four different gadolinium-based MR contrast agents.
Okigawa T; Utsunomiya D; Tajiri S; Okumura S; Sasao A; Wada H; Oda S; Arimura H; Hayashida E; Urata J; Yamashita Y
Magn Reson Med Sci; 2014; 13(1):1-6. PubMed ID: 24492735
[TBL] [Abstract][Full Text] [Related]
2. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections.
Aran S; Shaqdan KW; Abujudeh HH
Clin Radiol; 2015 May; 70(5):466-75. PubMed ID: 25626627
[TBL] [Abstract][Full Text] [Related]
3. Frequency and Severity of Acute Allergic-Like Reactions to Intravenously Administered Gadolinium-Based Contrast Media in Children.
Forbes-Amrhein MM; Dillman JR; Trout AT; Koch BL; Dickerson JM; Giordano RM; Towbin AJ
Invest Radiol; 2018 May; 53(5):313-318. PubMed ID: 29337841
[TBL] [Abstract][Full Text] [Related]
4. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
5. Severe adverse reactions with contrast agents for magnetic resonance: clinical experience in 30,000 MR examinations.
De Ridder F; De Maeseneer M; Stadnik T; Luypaert R; Osteaux M
JBR-BTR; 2001 Aug; 84(4):150-2. PubMed ID: 11688727
[TBL] [Abstract][Full Text] [Related]
6. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
[TBL] [Abstract][Full Text] [Related]
7. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections.
Abujudeh HH; Kosaraju VK; Kaewlai R
AJR Am J Roentgenol; 2010 Feb; 194(2):430-4. PubMed ID: 20093606
[TBL] [Abstract][Full Text] [Related]
8. Gadoxetate Disodium versus Gadoterate Meglumine: Quantitative Respiratory and Hemodynamic Metrics by Using Compressed-Sensing MRI.
Glessgen CG; Moor M; Stieltjes B; Winkel DJ; Block TK; Merkle EM; Heye TJ; Boll DT
Radiology; 2019 Nov; 293(2):317-326. PubMed ID: 31549944
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors.
Murphy KP; Szopinski KT; Cohan RH; Mermillod B; Ellis JH
Acad Radiol; 1999 Nov; 6(11):656-64. PubMed ID: 10894068
[TBL] [Abstract][Full Text] [Related]
10. Dosage of gadoteridol and adverse reactions relative to gadopentetate.
Hieronim DE; Kanal E; Swanson DP
Am J Health Syst Pharm; 1995 Nov; 52(22):2556-9. PubMed ID: 8590239
[TBL] [Abstract][Full Text] [Related]
11. [Comparative studies of the tolerability of gadodiamide, dimeglumine gadopentetate and meglumine gadoterate in MRI tests of the central nervous system].
Chanalet S; Masson B; Boyer L; Laffont J; Bruneton JN
J Radiol; 1995 Jul; 76(7):417-21. PubMed ID: 7473375
[TBL] [Abstract][Full Text] [Related]
12. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan.
Ishiguchi T; Takahashi S
Drugs R D; 2010; 10(3):133-45. PubMed ID: 20945944
[TBL] [Abstract][Full Text] [Related]
13. Relationship Between Patient-Friendly Audiovisual Systems and MRI Contrast Agent to Adverse Reactions.
Nitta K; Matsumoto K; Yokota H; Murata T; Masuda Y; Uno T
J Magn Reson Imaging; 2024 Jun; 59(6):2013-2020. PubMed ID: 37572088
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
15. Clinical safety of gadopentetate dimeglumine.
Nelson KL; Gifford LM; Lauber-Huber C; Gross CA; Lasser TA
Radiology; 1995 Aug; 196(2):439-43. PubMed ID: 7617858
[TBL] [Abstract][Full Text] [Related]
16. Reactions to Both Nonionic Iodinated and Gadolinium-Based Contrast Media: Incidence and Clinical Characteristics.
Sodagari F; Mozaffary A; Wood CG; Schmitz B; Miller FH; Yaghmai V
AJR Am J Roentgenol; 2018 Apr; 210(4):715-719. PubMed ID: 29412016
[TBL] [Abstract][Full Text] [Related]
17. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
18. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
19. Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients from the EuroCMR Registry.
Bruder O; Schneider S; Nothnagel D; Pilz G; Lombardi M; Sinha A; Wagner A; Dill T; Frank H; van Rossum A; Schwitter J; Nagel E; Senges J; Sabin G; Sechtem U; Mahrholdt H
JACC Cardiovasc Imaging; 2011 Nov; 4(11):1171-6. PubMed ID: 22093267
[TBL] [Abstract][Full Text] [Related]
20. Acute side effects of three commonly used gadolinium contrast agents in the paediatric population.
Neeley C; Moritz M; Brown JJ; Zhou Y
Br J Radiol; 2016 Jul; 89(1063):20160027. PubMed ID: 27194459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
